NASDAQ : ABSI
Absci Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 11.13 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.91B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.66B |
| Enterprise Value | 1.47B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 171.61M |
| Shares Outstanding | 171.61M |
| Shares Change (YoY) | +25.96% |
| Shares Change (QoQ) | +2.95% |
| Owned by Insiders (%) | 4.66% |
| Owned by Institutions (%) | 94.49% |
| Float | 163.61M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,065.30 |
| Forward PS | 193.53 |
| PB Ratio | 7.76 |
| P/TBV Ratio | 8.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 938.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.63 |
| Quick Ratio | 10.26 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,389.36 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -57.72% |
| Return on Assets (ROA) | -34.10% |
| Return on Invested Capital (ROIC) | -37.90% |
| Return on Capital Employed (ROCE) | -52.38% |
| Weighted Average Cost of Capital (WACC) | 16.76% |
| Revenue Per Employee | $11,150 |
| Profits Per Employee | -$864,836 |
| Employee Count | 140 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.28 |
| 52-Week Price Change | +126.40% |
| 50-Day Moving Average | 9.51 |
| 200-Day Moving Average | 6.52 |
| Relative Strength Index (RSI) | 48.76 |
| Average Volume (20 Days) | 4,066,812 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 37.02M |
| Short Previous Month | 37.44M |
| Short % of Shares Out | 21.57% |
| Short % of Float | 22.62% |
| Short Ratio (days to cover) | 8.22 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.56M |
| Gross Profit | -84.23M |
| Operating Income | -130.60M |
| Pretax Income | -121.08M |
| Net Income | -121.08M |
| EBITDA | -119.51M |
| EBIT | -130.60M |
| Loss Per Share | -$0.80 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 201.14M |
| Total Debt | 3.83M |
| Net Cash | 197.31M |
| Net Cash Per Share | $1.15 |
| Equity (Book Value) | 246.13M |
| Book Value Per Share | 1.43 |
| Working Capital | 188.67M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -108.08M |
| Capital Expenditures | -890,000 |
| Depreciation & Amortization | 11.09M |
| Net Borrowing | -2.00M |
| Free Cash Flow | -108.97M |
| FCF Per Share | -$0.63 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -8,366.43% |
| Pretax Margin | -7,756.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -25.96% |
| Shareholder Yield | -25.96% |
| Earnings Yield | -8.25% |
| FCF Yield | -6.55% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.82 |
| Price Target Difference | 52.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 120.83% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 10.54 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |